Genscript Biotech Beheer

Beheer criteriumcontroles 1/4

De CEO Genscript Biotech is Weihui Shao, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.48M, bestaande uit 14.3% salaris en 85.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.034% van de aandelen van het bedrijf, ter waarde HK$ 7.65M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 1.7 jaar.

Belangrijke informatie

Weihui Shao

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	14.3%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	1.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Weihui Shao's beloning veranderd ten opzichte van Genscript Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

Compensatie versus markt: De totale vergoeding ($USD 2.48M ) Weihui } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 481.50K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Weihui te vergelijken met de prestaties van het bedrijf.

CEO

Weihui Shao (44 yo)

3.3yrs

Tenure

US$2,477,000

Compensatie

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% HK$ 3.0m
Weihui Shao	CEO & COO	3.3yrs	US$2.48m	0.034% HK$ 7.7m
Ye Wang	Co-Founder	22.8yrs	US$659.00k	0.036% HK$ 8.3m
Luquan Wang	Co-Founder & Non-Executive Director	no data	geen gegevens	0.030% HK$ 6.8m
Fangliang Zhang	Co-Founder & Executive Director	1.9yrs	US$531.00k	geen gegevens
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% HK$ 12.2m
Shiniu Wei	Chief Financial Officer	3.9yrs	geen gegevens	geen gegevens
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	no data	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1548 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% HK$ 3.0m
Ye Wang	Co-Founder	9.5yrs	US$659.00k	0.036% HK$ 8.3m
Luquan Wang	Co-Founder & Non-Executive Director	9.5yrs	geen gegevens	0.030% HK$ 6.8m
Fangliang Zhang	Co-Founder & Executive Director	2.5yrs	US$531.00k	geen gegevens
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% HK$ 12.2m
Carl June	Member of Advisory Board	less than a year	geen gegevens	geen gegevens
George Church	Member of Advisory Board	5.2yrs	geen gegevens	geen gegevens
Alphonse Galdes	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
David Liu	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Chenyang Shi	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Ethan Pan	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1548 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw bestuur.

Genscript Biotech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 21% overvalued after recent price rise

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

New minor risk - Share price stability

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam